Latest news
Jazz Seeks FDA Withdrawal of Second-Line Lurbinectedin SCLC Indication - MedscapeMedscape · Fri, 07 Aug 2026 08:24:31 GMTLurbinectedin Second-Line SCLC Indication to Be Withdrawn After LAGOON - Targeted OncologyTargeted Oncology · Wed, 05 Aug 2026 14:09:27 GMTRecon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca - RAPSRAPS · Tue, 04 Aug 2026 20:19:00 GMTJazz to withdraw Zepzelca with FDA in second-line small cell lung cancer - Fierce PharmaFierce Pharma · Tue, 04 Aug 2026 13:18:16 GMTPHM: Recurring revenue up 18% and net profit at €0.6M, with ZepzelcaⓇ driving growth - TradingViewTradingView · Thu, 30 Jul 2026 10:56:34 GMT